$BLTE

$145.72 +$2.37 (1.65%) Close

$BLTE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 39.3M shares outstanding

Who owns BLTE?

By type of holder

Institutions 24.1% Insiders 0.0% Everyone else 75.9%

Concentration Top 10 holders own 18.4%

Darwin Global Management, Ltd. 7.8% · Paradigm Biocapital Advisors LP 3.1%

Institutional ownership

24.1%

+0.9 pts vs last qtr

Institutional holders

+5 vs last qtr

Net shares bought

+356.9K

by institutions in Q2 2026

New / sold out

21 / 16

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Maverick Capital LTD NEW +396.3K
Logos Global Management LP NEW +250.0K

Biggest sellers in Q2 2026

UBS Group AG −543.4K
Holocene Advisors, LP −243.5K

Who is planning to sell?

Notices of proposed sale, last 12 months

$90M

9 notices from 6 people

Shares covered

507.5K

1.29% of the company

Arranged in advance

94%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Yu-Hsin Lin Ceo, chairman 10b5-1 $46.8M
Hao-Yuan Chuang Officer, director 10b5-1 $34.5M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+281.5%

+30.71% a year

Each share's claim on the business

−73.8%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $56.1M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years3% 1–3 years7% Under 1 year90%

Quarterly turnover

18.4%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting BLTE on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
DG Darwin Global Management, Ltd.	3.1M	7.82%	+19.8K (+0.6%)	Q4 '25	12.1%
Shares held by quarter Peak holding3.1M (Q2'26) Change over 8 quarters+3.1M Share of the company7.820% Darwin Global Management, Ltd.'s full portfolio →
PB Paradigm Biocapital Advisors LP	1.2M	3.13%	+118.1K (+10.6%)	Q1 '26	3.6%
Shares held by quarter Peak holding1.2M (Q2'26) Change over 8 quarters+1.2M Share of the company3.130% Paradigm Biocapital Advisors LP's full portfolio →

Darwin Global Management, Ltd.

3.1M

% of company

7.82%

Change vs last qtr

+19.8K (+0.6%)

Held since

Q4 '25

Paradigm Biocapital Advisors LP

1.2M

% of company

3.13%

Change vs last qtr

+118.1K (+10.6%)

Held since

Q1 '26

28 more super investors behind a free account

See every manager holding Belite Bio, Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting BLTE on Form N-PORT; together they hold 0.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
TR T. Rowe Price Health Sciences Fund, Inc. T. Rowe Price Health Sciences Fund, Inc.	$12.4M	80.5K	0.20%	0.10%	June 30, 2026
AS Alger Small Cap Focus Fund Alger Funds	$9.85M	61.9K	0.16%	1.25%	April 30, 2026

T. Rowe Price Health Sciences Fund, Inc.

Position value

$12.4M

% of company

0.20%

% of the fund

0.10%

As of

June 30, 2026

Alger Small Cap Focus Fund

Alger Funds

Position value

$9.85M

% of company

0.16%

% of the fund

1.25%

As of

April 30, 2026

23 more funds behind a free account

See every fund holding Belite Bio, Inc and how much of the fund the position is.

Comments